24/7 Market News Snapshot 06 October, 2025 – Marker Therapeutics, Inc. Common Stock (NASDAQ:MRKR)

October 6, 2025

DENVER, Colo., 06 October, 2025 (www.247marketnews.com) – (NASDAQ:MRKR) are discussed in this article.
Marker Therapeutics, Inc. (MRKR) has seen a surge in trading activity, with shares opening at $1.015 and achieving a notable increase to $1.065, reflecting an 11.53% rise from the previous close of $0.955. This significant movement indicates a strong bullish sentiment in the market, driven by an increase in trading volume, which currently stands at 701.02K. Analysts suggest that key resistance levels may be encountered around $1.10, while immediate support is expected at the opening price of $1.015, making these values critical for traders seeking breakout or reversal opportunities amid anticipated volatility.

In parallel to its market performance, Marker Therapeutics has initiated a landmark Phase 1 RAPID study, assessing the safety and efficacy of its Off-the-Shelf (OTS) multi-antigen recognizing (MAR) T cell product, MT-401. The groundbreaking trial has already witnessed its first patient receiving treatment, marking a crucial step in the evaluation of this innovative therapy designed to target four tumor antigens prevalent in aggressive malignancies. Initial safety data has been encouraging, showing no treatment-related adverse events during the initial 28-day monitoring period, consistent with the favorable safety profile previously observed in MAR-T cell research.

Dr. Juan Vera, President and CEO of Marker Therapeutics, emphasized the significance of launching the OTS program as a critical advancement in addressing the prolonged manufacturing times associated with personalized cell therapies. By leveraging commercially sourced leukapheresis material from healthy donors, Marker Therapeutics aims to expedite the delivery of therapeutic solutions to patients battling aggressive cancers, potentially reducing the time from treatment initiation to administration to just 72 hours.

The program, supported by non-dilutive funding from notable agencies such as the FDA and NIH, underscores Marker Therapeutics’ commitment to improving patient outcomes through innovative T cell therapies and paves the way for future advancements in cancer treatment.

Related news for (MRKR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.